Relationship Between Circulating Sclerostin & Bone Lesions in Patients

Status Recruiting

Clinical Trial Summary

Mastocytosis is very rare and highly heterogeneous group of disorders, characterized by the accumulation of clonal mast cells which can infiltrate several organs and tissues. Bones are the most frequent localization of systemic mastocytosis. The aim of our research was to explain the potential role of sclerostin in the pathogenesis of bone disease in mastocytosis.

Clinical Trial Description

Mastocytosis is a heterogeneous group of disorders, characterized by the accumulation of clonal mast cells which can infiltrate several organs, such as the skin, bone marrow or liver. The skeleton is the most frequent localization of systemic mastocytosis (SM). Bone involvement occurs in approximately 70% of SM patients. Pathogenesis of mastocytosis bone disease is poorly understood. The aim of our research is to explain the potential role of sclerostin, a recently discovered bone tissue protein, in the pathogenesis of bone changes in patients with mastocytosis. The study group consists of adult patients with mastocytosis divided according to their clinical variants of disease (aggressive systemic mastocytosis - ASM, systemic mastocytosis with an associated hematological neoplasms SM-AHN, smouldering systemic mastocytosis - SSM, indolent systemic mastocytosis - ISM and cutaneous mastocytosis - CM; and group of healthy volunteers. The concentration of sclerostin, bioactive sclerostin and expression of the SOST gene in human plasma and HMC-1.2 human mast cell culture supernatants is assessed. The Real-Time PCR method is used to evaluate the expression of sclerostin at the mRNA level, while the concentration of the sclerostin protein and its bioactive form is assessed using the enzyme immunoassay ELISA method. The obtained results are correlated with selected demographic, clinical, laboratory and radiological findings. Low-dose CT scan is used to assess bone changes. These preliminary results could serve that sclerostin may be a new therapeutic target in patients with mastocytosis. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06440148
Study type	Observational
Source	Medical University of Lublin
Contact	Aneta Szudy-Szczyrek, MD., PhD.
Phone	+48815345468
Email	aneta.szudy-szczyrek@umlub.pl
Status	Recruiting
Phase
Start date	September 1, 2019
Completion date	December 31, 2026

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01333293` - The Effect of Xolair ® (Omalizumab) in Mastocytosis Patients	Phase 2/Phase 3
Completed	`NCT01481909` - Study on Mastocytosis for Rupatadine Treatment	Phase 2/Phase 3
Recruiting	`NCT00044122` - Study of Factors Regulating Mast Cell Proliferation
Recruiting	`NCT03340155` - Mechanisms of Action of Photo(Chemo)Therapy in Skin Diseases	N/A
Not yet recruiting	`NCT05084872` - Hydroxychloroquine in Isolated Cutaneous Mastocytosis Patients or Indolent Systemic Mastocytosis With Associated Skin Involvement Patients	Phase 2/Phase 3
Terminated	`NCT01701843` - Cromoglicate in Mastocytosis	Phase 2
Completed	`NCT00831974` - Efficacy of AB1010 in Patients With Systemic Indolent Mastocytosis	Phase 2
Completed	`NCT00047918` - Blood Factors in Mastocytosis and Unexplained Anaphylaxis and Flushing	N/A
Completed	`NCT00006413` - Stem Cell Transplantation to Treat Systemic Mastocytosis	Phase 2
Completed	`NCT00050193` - Cause and Natural Course of Pediatric-Onset Mastocytosis
Completed	`NCT02620254` - Mast Cell Connect: A Registry for Patients With Mastocytosis
Completed	`NCT00255346` - Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)	Phase 2
Completed	`NCT00001356` - Characteristics of Mast Cells in Mastocytosis	N/A
Recruiting	`NCT05186753` - (Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis	Phase 2
Completed	`NCT02478957` - Treatment of Indolent Systemic Mastocytosis With PA101	Phase 2
Recruiting	`NCT02450396` - Pregnancy and Medically Assisted Conception in Rare Diseases
Completed	`NCT00038675` - Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib Mesylate	N/A
Not yet recruiting	`NCT06432556` - Study of Cellular Heterogeneity in Patients With Mastocytosis	N/A
Completed	`NCT00336076` - Molecular Mechanisms and Diagnosis of Mastocytosis	N/A
Recruiting	`NCT04615663` - Assessment of Burden Disease in Patients With Mast Cell Disorders

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Relationship Between Circulating Sclerostin and Bone Lesions in Patients With Mastocytosis

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms